Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer
Authors:
Open Access
- 3 April 2012
- journal article
- Published by Wiley in Cancer Science
- Vol. 103 (5) , 959-967
Abstract
Breast cancer resistance protein (BCRP) plays a major role in multidrug resistance (MDR). Sequence analysis reveals there is a novel progesterone response element (PRE) in the BCRP promoter, suggesting progesterone receptor (PR) may have a function in the regulation of BCRP expression. We examined the expressions of BCRP, PR, estrogen receptor α (ERα), androgen receptor (AR) and Her‐2 in 95 breast cancer samples by immunohistochemistry. Then, to identify the role of PR in the regulation of BCRP expression, two constructs encoding full length BCRP cDNA driven by putative PRE promoter or constitutive CMV promoter were transfected into MCF‐7 and MDA‐MB‐231, respectively. Reverse transcription‐polymerase chain reaction (RT‐PCR) and western blotting were used to detect the expression of BCRP. Further electrophoretic mobility shift assay (EMSA) was used to verify the nuclear protein‐DNA specific binding. We innovatively found that the expression of BCRP negatively related with that of PR and ERα in breast cancer by immunohistochemistry. While at a cellular level, after being treated by progesterone and 17β‐estradiol, BCRP mRNA and protein levels were significantly reduced in a concentration‐dependent manner in MCF‐7/P‐BCRP cells with PR bound to the identified PRE in BCRP promoter. Our results demonstrated that active PR inactived BCRP expression via progesterone‐PR complexes binding to PRE in BCRP promoter in breast cancer cells. (Cancer Sci 2012; 103: 959–967)Keywords
This publication has 26 references indexed in Scilit:
- Estrogen Receptor β Signaling through Phosphatase and Tensin Homolog/Phosphoinositide 3-Kinase/Akt/Glycogen Synthase Kinase 3 Down-Regulates Blood-Brain Barrier Breast Cancer Resistance ProteinThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of GliomasCancer Research, 2010
- Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2010
- Membrane Topology of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) Determined by Epitope Insertion and ImmunofluorescenceBiochemistry, 2008
- Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancerCochrane Database of Systematic Reviews, 2006
- Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissuesCancer Letters, 2006
- Breast Cancer Resistance Protein–Mediated Efflux of Androgen in Putative Benign and Malignant Prostate Stem CellsCancer Research, 2005
- Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein ( ABCG2 ) GeneCancer Research, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Progesterone action and responses in the αERKO mouseSteroids, 2000